Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Oct 15;7(5):341-345.
eCollection 2019.

Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report

Affiliations
Case Reports

Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report

Yunshin A Yeh et al. Am J Clin Exp Urol. .

Abstract

TMPRSS2-ERG gene fusion occurs in approximately 50% of prostatic adenocarcinoma and their expression is associated with aggressive phenotype, higher tumor stage, and tumor metastasis. A case of prostatic adenocarcinoma with IRF2BP2-NTRK1 translocation was previously reported. We report a prostatic adenocarcinoma with novel NTRK3 gene fusion that occurs in a 71-year-old male patient with aggressive histologic phenotype and multiple bony metastases. Prostatic biopsy revealed that there is a prostatic adenocarcinoma with a Gleason score of 9 (4+5), grade group 5, and multiple sites of perineural and ganglional invasion. Fluorescence in-situ hybridization (FISH) and next-generation sequencing were performed. FISH studies showed a breakage within the NTRK3 gene in prostatic adenocarcinoma cells. Next-generation sequencing confirmed that there is a PRPSAP1-NTRK3 translocation in the prostatic adenocarcinoma. In addition, ASXL1, KIF5B, MED12, PIK3CA mutations were found. NTRK alterations or dysregulation of PI3K signaling pathway were found in many types of cancers. TRK inhibitors including larotrectinib and entrectinib were approved by the US Food and Drug Administration for treating TRK fusion-positive malignant tumors and PI3K/AKT/mTOR pathway inhibitors were under clinical studies on various cancers including prostate cancer. In our current case, both NTRK3 and PIK3CA may serve as biomarkers for precision targeted therapy.

Keywords: NTRK3; PI3K; PIK3CA; PRPSAP1-NTRK3; Prostatic adenocarcinoma; TMPRSS2-ERG; translocations.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Histopathological features of prostatic adenocarcinoma. A. The prostatic core shows 80% involvement by prostatic adenocarcinoma, Gleason score 9 (4+5), grade group 5 (H&E, 40×). B. The prostatic carcinomas are composed of fusion glands arranged in a cribriform pattern (H&E, 100×). C. The adenocarcinoma cells are characterized by hyperchromatic nuclei containing one or more nucleoli, consistent with Gleason pattern 4 (H&E, 400×). D. Focal areas of adenocarcinoma show dispersed carcinoma cells with hyperchromatic nuclei and scanty cytoplasm, consistent with Gleason pattern 5 (H&E, 400×). E. Multiple areas demonstrate perineural invasion (H&E, 200×). F. Invasion of ganglional cells is evident (H&E, 400×).
Figure 2
Figure 2
Fluorescence in-situ hybridization (FISH) of NTRK3 “break-apart” probe. A. The red signal (yellow arrows) shows that the NTRK3 “break-apart” FISH probe targeting the 3’ terminal region. B. The green signal (yellow arrow) reveals that the NTRK3 “break-apart” FISH probe targeting the 5’ terminal region. C. The blue staining represents DAPI nuclear stain. D. The red and green signals (yellow arrows) demonstrate the two separately located NTRK3 “break-apart” FISH probes. These results indicate a breakage of the NTRK3.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. - PubMed
    1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648. - PubMed
    1. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497–511. - PMC - PubMed
    1. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396–3400. - PubMed
    1. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM. Characterization of TMPRSS2: ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68:73–80. - PubMed

Publication types

LinkOut - more resources